Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Deloitte
Daiichi Sankyo
AstraZeneca
Baxter
UBS
Cantor Fitzgerald
Queensland Health
Teva

Generated: December 11, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR EDARAVONE

« Back to Dashboard

Clinical Trials for Edaravone

Trial ID Title Status Sponsor Phase Summary
NCT00153946 Edaravone and Argatroban Stroke Therapy Study for Acute Ischemic Stroke Completed Japan Cardiovascular Research Foundation Phase 4 Edaravone, a free radical scavenger, is a novel neuroprotective agent, and argatroban is a selective thrombin inhibitor. Both the drugs were approved by the Japanese Government, and have frequently been used for the treatment of acute brain infarction in Japan. The effect of combination therapy of these drugs, however, has not yet been elucidated. This study will test the safety and efficacy of the combination therapy with these agents in patients with acute non-cardioembolic and non-lacunar ischemic stroke.
NCT00153946 Edaravone and Argatroban Stroke Therapy Study for Acute Ischemic Stroke Completed Combination Therapy for Acute Ischemic Stroke Study Group Phase 4 Edaravone, a free radical scavenger, is a novel neuroprotective agent, and argatroban is a selective thrombin inhibitor. Both the drugs were approved by the Japanese Government, and have frequently been used for the treatment of acute brain infarction in Japan. The effect of combination therapy of these drugs, however, has not yet been elucidated. This study will test the safety and efficacy of the combination therapy with these agents in patients with acute non-cardioembolic and non-lacunar ischemic stroke.
NCT00200356 Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke Completed Mitsubishi Tanabe Pharma Corporation Phase 4 This study is randomized, Sodium Ozagrel (Thromboxane A2 Synthase Inhibitor) controlled study on acute ischemic stroke. The primary endpoints were the rate of patients with modified Rankin Scale score of 0-1 at 3 months.
NCT00265239 Pilot Study of Edaravone to Treat Acute Myocardial Infarction Completed Japan Heart Foundation Phase 4 Early reperfusion therapy has improved the clinical outcomes of patients with acute myocardial infarction (AMI), but these benefits are limited in some patients by reperfusion injuries. There is now increasing evidence that reactive oxygen species cause reperfusion injury. This study was designed to examine the effects of edaravone, a novel free radical scavenger, in patients with AMI.
NCT00265239 Pilot Study of Edaravone to Treat Acute Myocardial Infarction Completed Kumamoto University Phase 4 Early reperfusion therapy has improved the clinical outcomes of patients with acute myocardial infarction (AMI), but these benefits are limited in some patients by reperfusion injuries. There is now increasing evidence that reactive oxygen species cause reperfusion injury. This study was designed to examine the effects of edaravone, a novel free radical scavenger, in patients with AMI.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Edaravone

Condition Name

Condition Name for Edaravone
Intervention Trials
Amyotrophic Lateral Sclerosis (ALS) 3
Stroke 2
ALS 2
Healthy 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Edaravone
Intervention Trials
Amyotrophic Lateral Sclerosis 6
Motor Neuron Disease 6
Sclerosis 5
Stroke 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Edaravone

Trials by Country

Trials by Country for Edaravone
Location Trials
China 35
Japan 5
United States 1
Netherlands 1
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Edaravone
Location Trials
Kansas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Edaravone

Clinical Trial Phase

Clinical Trial Phase for Edaravone
Clinical Trial Phase Trials
Phase 4 3
Phase 3 4
Phase 2 5
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Edaravone
Clinical Trial Phase Trials
Completed 9
Recruiting 4
Unknown status 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Edaravone

Sponsor Name

Sponsor Name for Edaravone
Sponsor Trials
Mitsubishi Tanabe Pharma Corporation 7
Jiangsu Simcere Pharmaceutical Co., Ltd. 2
ALS Canada 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Edaravone
Sponsor Trials
Other 15
Industry 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Citi
Express Scripts
Moodys
Harvard Business School
Healthtrust
Fuji
Colorcon
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.